Ayala Pharmaceuticals Statistics
Total Valuation
ADXS has a market cap or net worth of $23.02 million. The enterprise value is $26.46 million.
| Market Cap | 23.02M |
| Enterprise Value | 26.46M |
Important Dates
The last earnings date was Monday, September 11, 2023, before market open.
| Earnings Date | Sep 11, 2023 |
| Ex-Dividend Date | n/a |
Share Statistics
ADXS has 42.63 million shares outstanding.
| Shares Outstanding | 42.63M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 0.02% |
| Owned by Institutions (%) | 16.65% |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1,770.93 |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2,035.08 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.30
| Current Ratio | 0.30 |
| Quick Ratio | n/a |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | 70.23 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -289.96% |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | $929 |
| Profits Per Employee | -$3.43M |
| Employee Count | 14 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -3.91M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -58.14% in the last 52 weeks.
| Beta (1Y) | n/a |
| 52-Week Price Change | -58.14% |
| 50-Day Moving Average | 0.69 |
| 200-Day Moving Average | 0.83 |
| Relative Strength Index (RSI) | 38.56 |
| Average Volume (30 Days) | 22,800 |
Short Selling Information
The latest short interest is 80,341, so 0.19% of the outstanding shares have been sold short.
| Short Interest | 80,341 |
| Short Previous Month | 74,009 |
| Short % of Shares Out | 0.19% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 1.57 |
Income Statement
In the last 12 months, ADXS had revenue of $13,000 and -$48.07 million in losses. Loss per share was -$5.02.
| Revenue | 13,000 |
| Gross Profit | -7.13M |
| Operating Income | -36.27M |
| Pretax Income | -51.98M |
| Net Income | -48.07M |
| EBITDA | -35.92M |
| EBIT | -36.24M |
| Loss Per Share | -$5.02 |
Balance Sheet
The company has $4.88 million in cash and $8.32 million in debt, giving a net cash position of -$3.43 million or -$0.08 per share.
| Cash & Cash Equivalents | 4.88M |
| Total Debt | 8.32M |
| Net Cash | -3.43M |
| Net Cash Per Share | -$0.08 |
| Equity / Book Value | -24.42M |
| Book Value Per Share | -0.57 |
| Working Capital | -17.49M |
Cash Flow
| Operating Cash Flow | -20.92M |
| Capital Expenditures | n/a |
| Free Cash Flow | -20.92M |
| FCF Per Share | -$0.49 |
Margins
Gross margin is -54,853.85%, with operating and profit margins of -278,969.23% and -369,784.62%.
| Gross Margin | -54,853.85% |
| Operating Margin | -278,969.23% |
| Pretax Margin | -399,876.92% |
| Profit Margin | -369,784.62% |
| EBITDA Margin | -276,338.46% |
| EBIT Margin | -278,753.85% |
| FCF Margin | -160,953.85% |
Dividends & Yields
ADXS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -208.81% |
| FCF Yield | -90.89% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | Hold |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on June 6, 2022. It was a reverse split with a ratio of 1:80.
| Last Split Date | Jun 6, 2022 |
| Split Type | Reverse |
| Split Ratio | 1:80 |
Scores
ADXS has an Altman Z-Score of -24.8 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -24.8 |
| Piotroski F-Score | 1 |